Today’s Research Reports on Trending Tickers: AVEO Pharmaceuticals and Neovasc

NEW YORK, NY / ACCESSWIRE / April 6, 2018 / U.S. markets ended higher on Thursday for their third straight daily gain as technology stocks recover from a series of shortcomings. The Dow Jones Industrial Average rose to 24,505.22, an increase of 0.99 percent, while the S&P 500 Index gained 0.69 percent to close at 2,662.84, led by a 1.8% gain for energy as crude prices gained, and a 1.9% climb in the materials sector. The Nasdaq Composite Index jumped 0.49 percent to close at 7,076.55. Gains in the Nasdaq were short as weakness in chip makers pressured the overall technology sector.

RDI Initiates Coverage on:

AVEO Pharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=AVEO

Neovasc Inc.
https://rdinvesting.com/news/?ticker=NVCN

AVEO Pharmaceuticals’ stock fell 10.27% Thursday, to close the day at $2.36. The stock recorded a trading volume of 3,444,859 shares, which was above its three months average volume of 1,731,367 shares. In the last year, AVEO Pharmaceuticals’ shares have traded in a range of 0.55 – 4.24. The share price has gained 329.09% from its 52 week low. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $2.87 is below its 200-day moving average of $3.05. Shares of AVEO Pharmaceuticals have fallen roughly 16.90 percent in the past month and are down 15.41 percent year-to-date.

Access RDI’s AVEO Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=AVEO

On Thursday, shares of Neovasc recorded a trading volume of 202,661,748 shares, which was above the three months average volume of 30,566,918 shares. The stock ended the day 14.48% higher at 0.04. The share price has gained 37.00% from its 52-week low with a 52-week trading range of 0.03 – 1.89. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $0.16 is below its 200-day moving average of $0.78. Shares of the company are trading at a Price to Earnings ratio of 0.16. Shares of Neovasc have fallen roughly 80.95 percent in the past month and are down 93.33 percent year-to-date.

Access RDI’s Neovasc Inc. Research Report at:
https://rdinvesting.com/news/?ticker=NVCN

Our Actionable Research on AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) and Neovasc Inc. (NASDAQ:NVCN) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 495348